4.5 Article

Cognitive/Functional Measures Predict Alzheimer's Disease, Dependent on Hippocampal Volume

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/geronb/gbz011

Keywords

Brain/cognitive reserve; Hippocampus; Mild cognitive impairment; MRI; Neuropsychological tests

Funding

  1. Alzheimer's Disease Neuroimaging Initiative (ADNI
  2. National Institutes of Health) [U01 AG024904]
  3. National Institute on Aging
  4. National Institute of Biomedical Imaging and Bioengineering
  5. Alzheimer's Association
  6. Alzheimer Drug Discovery Foundation
  7. BioClinica, Inc.
  8. Biogen Idec, Inc.
  9. BristolMyers Squibb Company
  10. Eisai, Inc.
  11. Elan Pharmaceuticals, Inc.
  12. Eli Lilly and Company
  13. F. Hoffmann-La Roche Ltd
  14. Genentech, Inc.
  15. GE Healthcare
  16. Innogenetics, N.V.
  17. IXICO Ltd.
  18. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  19. Johnson & Johnson Pharmaceutical Research & Development LLC.
  20. Medpace, Inc.
  21. Merck Co., Inc.
  22. Meso Scale Diagnostics, LLC.
  23. Neu-roRx Research
  24. Novartis Pharmaceuticals Corporation
  25. Pfizer, Inc.
  26. Piramal Imaging
  27. Servier
  28. Synarc, Inc.
  29. Takeda Pharmaceutical Company
  30. Canadian Institutes of Health Research
  31. Australian Commonwealth Government
  32. Australian Government Research Training Program (RTP) Scholarship

Ask authors/readers for more resources

Objectives: This study aimed to investigate the predictive value of cognitive/functional measures in combination with hippocampal volume (HCV) on the probability of conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD). Methods: The Rey Auditory Verbal Learning Test for immediate memory, Mini-Mental State Examination, a functional assessment for independent daily activities and Alzheimer's Disease Assessment Scale were used as cognitive/functional measures and HCV as neuroimaging measure. Logistic regression and Cox proportional hazard analyses were used to explore the measures' predictive values for AD conversion and time to conversion. Results: The probability of conversion from MCI to AD was associated with cognitive function, but this was moderated by HCV: higher at lower HCV and lower at higher HCV. General cognitive/functional measures were less predictive than immediate memory in predicting time to conversion to AD at small HCVs. Conclusion: Effectiveness of cognitive measures and subtle functional abnormality in predicting conversion from MCI to AD is dependent on HCV, thus combined evaluation should be considered. A combination of HCV and immediate memory appear to perform best in predicting time to conversion.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available